CHAMPIX Film-coated tablets (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
CHAMPIX 0.5 mg film-coated tablets. CHAMPIX 1 mg film-coated tablets.
Qualitative and quantitative composition
Each 0.5 mg film-coated tablet contains 0.5 mg of varenicline (as tartrate). Each 1 mg film-coated tablet contains 1 mg of varenicline (as tartrate). For the full list of excipients, see section 6.1. ...
Pharmaceutical form
Film-coated tablets. 0.5 mg film-coated tablets of 4 mm x 8 mm: White, capsular-shaped, biconvex tablets debossed with Pfizer on one side and CHX 0.5 on the other side. 1 mg film-coated tablets of 5 mm ...
Therapeutic indications
CHAMPIX is indicated for smoking cessation in adults.
Posology and method of administration
Posology The recommended dose is 1 mg varenicline twice daily following a 1-week titration as follows: Days 1–3: 0.5 mg once daily. Days 4–7: 0.5 mg twice daily. Day 8–End of treatment: 1 mg twice ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
Effect of smoking cessation Physiological changes resulting from smoking cessation, with or without treatment with CHAMPIX, may alter the pharmacokinetics or pharmacodynamics of some medicinal products, ...
Interaction with other medicinal products and other forms of interaction
Based on varenicline characteristics and clinical experience to date, CHAMPIX has no clinically meaningful drug interactions. No dosage adjustment of CHAMPIX or co-administered medicinal products listed ...
Fertility, pregnancy and lactation
Pregnancy A moderate amount of data on pregnant women indicated no malformative or foetal/neonatal toxicity of varenicline (see section 5.1). Animal studies have shown reproductive toxicity (see section ...
Effects on ability to drive and use machines
CHAMPIX may have minor or moderate influence on the ability to drive and use machines. CHAMPIX may cause dizziness, somnolence and transient loss of consciousness, and therefore may influence the ability ...
Undesirable effects
Summary of the safety profile Smoking cessation with or without treatment is associated with various symptoms. For example, dysphoric or depressed mood; insomnia, irritability, frustration or anger; anxiety; ...
Overdose
No cases of overdose were reported in pre-marketing clinical trials. In case of overdose, standard supportive measures should be instituted as required. Varenicline has been shown to be dialyzed in patients ...
Pharmacodynamic properties
Pharmacotherapeutic group: Other nervous system drugs; Drugs used in addictive disorders; Drugs used in nicotine dependence ATC code: N07BA03 Mechanism of action Varenicline binds with high affinity and ...
Pharmacokinetic properties
Absorption Maximum plasma concentrations of varenicline occur typically within 3-4 hours after oral administration. Following administration of multiple oral doses to healthy volunteers, steady-state conditions ...
Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, fertility and embryo-foetal development. In male rats dosed ...
List of excipients
Tablets' core: 0.5 mg and 1 mg Tablets: Cellulose, microcrystalline Calcium hydrogen phosphate anhydrous Croscarmellose sodium Silica, colloidal anhydrous Magnesium stearate Film coating: 0.5 mg Tablet: ...
Incompatibilities
Not applicable.
Shelf life
Shelf life Bottles: 2 years. Blisters: 3 years.
Special precautions for storage
Blisters: Store below 30°C. HDPE Bottle: This medicinal product does not require any special storage conditions.
Nature and contents of container
Treatment initiation packs: PCTFE/PVC blisters with aluminium foil backing containing 1 clear blister of 11 0.5 mg film-coated tablets and a second clear blister of 14 1 mg film-coated tablets in secondary ...
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050, Bruxelles, Belgium
Marketing authorization number(s)
0.5 mg tablets: EU/1/06/360/001 EU/1/06/360/006 EU/1/06/360/007 EU/1/06/360/017 EU/1/06/360/018 1mg tablets: EU/1/06/360/002 EU/1/06/360/004 EU/1/06/360/005 EU/1/06/360/009 EU/1/06/360/010 EU/1/06/360/011 ...
Date of first authorization / renewal of the authorization
Date of first authorisation: 26 September 2006 Date of latest renewal: 29 June 2016
Date of revision of the text
07/2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
